EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the eff...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	V. P. Maksimova, J. V. Makus, O. G. Usalka, E. S. Lylova, P. E. Bugaeva, E. M. Zhidkova, D. A. Fedorov, O. P. Lizogub, E. A. Lesovaya, G. A. Belitsky, M. G. Yakubovskaya, K. I. Kirsanov
Μορφή:	Artigo
Γλώσσα:	Russo
Έκδοση:	Russian Academy of Sciences, Tomsk National Research Medical Center 2020-09-01
Σειρά:	Сибирский онкологический журнал
Θέματα:	protein kinase inhibitors enzastaurin epigenetic activity hela ti histone modifications dna methylation hat hdac
Διαθέσιμο Online:	https://www.siboncoj.ru/jour/article/view/1531
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!